


7-Hydroxyneolamellarin A

Cat. No.:	HY-N10330
CAS No.:	959662-26-1
Molecular Formula:	C ₂₄ H ₁₉ NO ₅
Molecular Weight:	401.41
Target:	HIF/HIF Prolyl-Hydroxylase; VEGFR
Pathway:	Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	7-Hydroxyneolamellarin A is a natural product that could be derived from sponge <i>Dendrilla nigra</i> . 7-Hydroxyneolamellarin A is a potent hypoxia-inducible factor-1 α (HIF-1 α) inhibitor. 7-Hydroxyneolamellarin A attenuates the accumulation of hypoxia-inducible factor-1 α (HIF-1 α) protein and inhibits vascular epidermal growth factor (VEGF) transcriptional activity. 7-Hydroxyneolamellarin A can be used in research of cancer ^[1] .								
In Vitro	<p>7-Hydroxyneolamellarin A (0-150 μM; 12 h; Hela cells, MCF-7 cells and 4T1 cells) inhibits HIF-1 signaling pathway with low cytotoxicity^[1].</p> <p>7-Hydroxyneolamellarin A (0-100 μM; 12 h) reduces the mRNA levels of VEGF dose-dependently in Hela cells^[1].</p> <p>7-hydroxyneolamellarin A (0-50 μM; 36 h) inhibits Hela cells migration, invasion and proliferation^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Hela cells, MCF-7 cells and 4T1 cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 50, 100, and 150 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>12 hours</td> </tr> <tr> <td>Result:</td> <td>Decreased the HIF-1α protein levels in a dose-dependent manner.</td> </tr> </table>	Cell Line:	Hela cells, MCF-7 cells and 4T1 cells	Concentration:	0, 50, 100, and 150 μ M	Incubation Time:	12 hours	Result:	Decreased the HIF-1 α protein levels in a dose-dependent manner.
Cell Line:	Hela cells, MCF-7 cells and 4T1 cells								
Concentration:	0, 50, 100, and 150 μ M								
Incubation Time:	12 hours								
Result:	Decreased the HIF-1 α protein levels in a dose-dependent manner.								
In Vivo	<p>7-Hydroxyneolamellarin A (15 mg/kg; i.v.; BALB/c mice with 4T1 cells xenografts) inhibits tumor growth in vivo^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>BALB/c mice with 4T1 cells xenografts^[1]</td> </tr> <tr> <td>Dosage:</td> <td>15 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; every 2 days for 16 days</td> </tr> <tr> <td>Result:</td> <td>Inhibited tumor growth in vivo.</td> </tr> </table>	Animal Model:	BALB/c mice with 4T1 cells xenografts ^[1]	Dosage:	15 mg/kg	Administration:	Intravenous injection; every 2 days for 16 days	Result:	Inhibited tumor growth in vivo.
Animal Model:	BALB/c mice with 4T1 cells xenografts ^[1]								
Dosage:	15 mg/kg								
Administration:	Intravenous injection; every 2 days for 16 days								
Result:	Inhibited tumor growth in vivo.								

REFERENCES

[1]. Li G, et, al. Total synthesis and biological evaluation of 7-hydroxyneolamellarin A as hypoxia-inducible factor-1 α inhibitor for cancer therapy. Bioorg Med Chem Lett. 2021 Oct 15;50:128338.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA